WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...

H.C. Wainwright adjusted the firm’s price target on Arqit Quantum (ARQQ) to $22 from $2 and keeps a Buy rating on the shares to reflect the ...

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on MediWound (MDWD) to $25 from $28 and keeps a Buy rating on ...

H.C. Wainwright has recently reduced Eyenovia Inc (EYEN) stock to Neutral rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 1, 2021, Northland Capital had initiated the ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

On Wednesday, Verrica Pharmaceuticals Inc (VRCA) stock saw a modest uptick, ending the day at $1.24 which represents a slight increase of $0.13 or 11.71% from the prior close of $1.11. The stock ...

H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Regenxbio (RGNX) to $36 from $40 and keeps a Buy rating on the shares after the ...

Bionomics Limited, an Australia-based company listed on the OTCMKTS under the symbol BNOEF, recently disclosed in an 8-K filing with the Securities and Exchange Commission that it has entered into an ...

H.C. Wainwright lowered the firm’s price target on Lexicon (LXRX) to $4 from $6 and keeps a Buy rating on the shares. The company announced that following a “deficiencies preclude discussion ...

We recently compiled a list of the 15 AI News That Should Not Be Ignored. In this article, we are going to take a look at ...

Kura (KURA) recently announced deal with Kirin Kyowa (KNBWY) for its leukemia drug ziftomenib was viewed favorably by ...

H.C. Wainwright says Pyxis Oncology (PYXS) reported positive preliminary data from the ongoing Phase 1 study of PYX-201, an extra domain B splice variant of fibronectin targeted antibody-drug ...